|
Market Closed -
Nasdaq
16:00:00 2026-10-20 EDT
|
5-day change | 1st Jan Change | ||
| 807.48 USD | +3.25% |
|
+5.86% | +4.61% |
| 10-20 | AstraZeneca-Amgen asthma drug hits 69% remission in esophageal disease trial | RE |
| 10-19 | Major drugmakers turn to China for licensing deals | RE |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Biopharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 78.09B | |||||
| 1,106B | |||||
| 612B | |||||
| 500B | |||||
| 367B | |||||
| 354B |
Select your edition
All financial news and data tailored to specific country editions
